[go: up one dir, main page]

WO1993001304A1 - Peptides synthetiques relatifs a des proteines d'enveloppe du vif - Google Patents

Peptides synthetiques relatifs a des proteines d'enveloppe du vif Download PDF

Info

Publication number
WO1993001304A1
WO1993001304A1 PCT/US1992/005689 US9205689W WO9301304A1 WO 1993001304 A1 WO1993001304 A1 WO 1993001304A1 US 9205689 W US9205689 W US 9205689W WO 9301304 A1 WO9301304 A1 WO 9301304A1
Authority
WO
WIPO (PCT)
Prior art keywords
phe
gln
peptide
glu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1992/005689
Other languages
English (en)
Inventor
Eric S. Bean
Darrell Peterson
Kathleen J. Bertul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synbiotics LLC
Original Assignee
Synbiotics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synbiotics LLC filed Critical Synbiotics LLC
Publication of WO1993001304A1 publication Critical patent/WO1993001304A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • This invention relates to non-naturally occurring or synthetic peptides which mimic an antigenic site on the surface of feline immunodeficiency virus (FIV) envelope protein.
  • FV feline immunodeficiency virus
  • feline immunodeficiency virus A retrovirus termed feline immunodeficiency virus (FIV) is now known to be the etiological agent in feline acquired immunodeficiency syndrome (FAIDS). Testing for FIV is important in diagnosing exposure to the virus in order to to limit the spread of infection.
  • FAIDS feline acquired immunodeficiency syndrome
  • Detection of exposure to FIV is accomplished by measuring levels of FIV antibodies in serum, plasma, whole blood or saliva.
  • inactivated crude or purified viral protein from lysates of FIV-infected cells are used to coat a solid phase.
  • Biological samples suspected of containing FIV antibodies are incubated with the solid phase and after an
  • anti-feline antibody tagged with a detectable label is added to the solid phase.
  • the label which may be an enzyme, radioisotope or fluorescent molecule is measured to determine the presence of FIV antibodies in the sample.
  • the difficulty with using viral lysates as a source of FIV antigens is the high level of
  • This invention provides a highly sensitive and accurate detection or diagnostic procedure that does not require the use of virus or lysates thereof as a test reagent.
  • a polypeptide test reagent prepared by chemical means is used to detect the presence of antibodies to FIV in body fluids.
  • test reagent comprising a peptide having about twenty seven amino acids arranged in a specific sequence, preferably prepared by solid phase
  • the 27mer peptide is useful in a highly sensitive and accurate method for the detection of antibodies to FIV in serum.
  • a shorter 13mer peptide contained within the 27mer is similarly useful.
  • Peptides having specific immunoreactivity to FIV antibodies are selected from the group consisting of peptides containing from twelve to twenty seven amino acids, the sequence of which corresponds to a part or the entirety of the following sequence
  • the highly sensitive and accurate method for the detection of antibodies to FIV in serum comprises the following steps:
  • a solid phase such as polystyrene
  • a buffered solution containing from about 0.5 ug/ml to about 20 ug/ml of peptide, in an appropriate solvent such as phosphate buffered or borate buffered saline.
  • a detectable label which may be an enzyme, radioisotope or fluorescent molecule.
  • Horseradish peroxidase was activated by periodate oxidation (20 mM sodium metaperiodate) for two hours at 25°C. Peptide was added to the activate enzyme and allowed to react for two hours at 25 °C and the resulting conjugate was stabilized by sodium
  • conjugation ratio of peptide to enzyme of 15-35 The conjugated peptide is diluted for use into a solution containing 10 mM phosphate, 6% (w/v) bovine serum albumin and 0.1% (v/v) Tween 20.
  • the working peptide is diluted for use into a solution containing 10 mM phosphate, 6% (w/v) bovine serum albumin and 0.1% (v/v) Tween 20.
  • conjugate concentration is from about 0.5 ug/ml to about 10 ug/ml.
  • IFA immunofluorescence assay

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des peptides nouveaux et utiles dans des tests de diagnostic du virus de l'immunodéficience féline (VIF).
PCT/US1992/005689 1991-07-10 1992-07-09 Peptides synthetiques relatifs a des proteines d'enveloppe du vif Ceased WO1993001304A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72813491A 1991-07-10 1991-07-10
US728,134 1991-07-10

Publications (1)

Publication Number Publication Date
WO1993001304A1 true WO1993001304A1 (fr) 1993-01-21

Family

ID=24925565

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/005689 Ceased WO1993001304A1 (fr) 1991-07-10 1992-07-09 Peptides synthetiques relatifs a des proteines d'enveloppe du vif

Country Status (1)

Country Link
WO (1) WO1993001304A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006471A1 (fr) * 1992-09-21 1994-03-31 Mallinckrodt Veterinary,Inc. Vaccins destines a lutter contre le virus immunodeficitaire felin
EP0602046A4 (fr) * 1991-06-14 1995-07-19 St Vincents Inst Med Res Detection des virus de l'immunodeficience chez les mammiferes.
FR2721031A1 (fr) * 1994-06-09 1995-12-15 Centre Nat Rech Scient Fragment peptidique spécifique du virus de l'immunodéficience féline (VIF) et son utilisation comme réactif de diagnostic.
FR2771011A1 (fr) * 1997-11-17 1999-05-21 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
US7201903B2 (en) 2003-09-11 2007-04-10 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
US7285278B2 (en) 2004-06-30 2007-10-23 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
US7285272B2 (en) 2003-12-18 2007-10-23 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
US7291338B2 (en) 2005-03-09 2007-11-06 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
US7335360B2 (en) 2004-06-30 2008-02-26 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
US7348136B2 (en) 2004-02-19 2008-03-25 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
US8809004B2 (en) 2010-04-02 2014-08-19 Idexx Laboratories, Inc. Detection of feline immunodeficiency virus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037753A (en) * 1987-08-26 1991-08-06 The Regents Of The University Of California Feline t-lymphotropic lentivirus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037753A (en) * 1987-08-26 1991-08-06 The Regents Of The University Of California Feline t-lymphotropic lentivirus
US5037753B1 (en) * 1987-08-26 1994-03-15 The Regents Of The University Of California Feline t-lymphotropic lentivirus
US5037753B2 (en) * 1987-08-26 1998-06-16 Univ California Feline t-lymphotrophic lentivirus

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF GENERAL VIROLOGY, Volume 71, issued 1990, H.F. EGBERINK et al., "Intracellular Proteins of Feline Immunodeficiency Virus and Their Antigenic Relationship with Equine Infectious Anaemia Virus Proteins", pages 739-743. *
JOURNAL OF GENERAL VIROLOGY, Volume 71, issued 1990, R. STEINMAN et al., "Biochemical and Immunological Characterization of the Major Structural Proteins of Feline Immunodeficiency Virus", pages 701-706. *
JOURNAL OF VIROLOGY, Volume 65, No. 3, issued March 1991, E.B. STEPHENS et al., "Processing of the Glycoprotein of Feline Immunodeficiency Virus: Effect of Inhibitors of Glycosylation", pages 1114-1123. *
JOURNAL OF VIROLOGY, Volume 65, No. 8, issued August 1991, T. KIYOMASU et al., "Identification of Feline Immunodeficiency Virus Rev Gene Activity", pages 4539-4542. *
MOLECULAR IMMUNOLOGY, Volume 29, No. 5, issued 1992, A.AVRAMEAS, "Localization of Three Epitopes of the Env Protein of Feline Immunodeficiency Virus", pages 565-572. *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, Volume 86, issued April 1989, R.A. OLMSTED et al., "Molecular Cloning of Feline Immunodeficiency Virus", pages 2448-2452. *
VIROLOGY, Volume 183, issued 1991, S. MORIKAWA et al., "Analysis of the Requirements for the Synthesis of Virus-Like Particles by Feline Immunodeficiency Virus Gag Using Baculovirus Vectors", pages 288-297. *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0602046A4 (fr) * 1991-06-14 1995-07-19 St Vincents Inst Med Res Detection des virus de l'immunodeficience chez les mammiferes.
US5591572A (en) * 1991-06-14 1997-01-07 St. Vincents Institute Of Medical Research Limited Detection of mammalian immunodeficiency viruses
WO1994006471A1 (fr) * 1992-09-21 1994-03-31 Mallinckrodt Veterinary,Inc. Vaccins destines a lutter contre le virus immunodeficitaire felin
FR2721031A1 (fr) * 1994-06-09 1995-12-15 Centre Nat Rech Scient Fragment peptidique spécifique du virus de l'immunodéficience féline (VIF) et son utilisation comme réactif de diagnostic.
EP0688790A1 (fr) * 1994-06-09 1995-12-27 Centre National De La Recherche Scientifique Fragment peptidique spécifique du virus de l'immunodéficience féline (VIF), et son utilisation comme réactif de diagnostic
US5648209A (en) * 1994-06-09 1997-07-15 Centre National De La Recherche Scientifique-Cnrs Specific peptide fragment of the feline immunodeficiency virus (FIV), and its use as a diagnostic reagent
US6455265B1 (en) 1997-11-17 2002-09-24 Mymetics S.A. Method for obtaining vaccines for preventing the pathogenic effects related to a retroviral infection
WO1999025377A1 (fr) * 1997-11-17 1999-05-27 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
FR2771011A1 (fr) * 1997-11-17 1999-05-21 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
US7253270B2 (en) 1997-11-17 2007-08-07 Mymetics Sa Polynucleotide encoding a mutated HIV gp41 polypeptide
US7829683B2 (en) 1997-11-17 2010-11-09 Lomastar Technologies Sarl Polynucleotides encoding modified HIV-1 gp41 membrane polypeptides
US7201903B2 (en) 2003-09-11 2007-04-10 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
US7776546B2 (en) 2003-09-11 2010-08-17 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
US7285272B2 (en) 2003-12-18 2007-10-23 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
US7348136B2 (en) 2004-02-19 2008-03-25 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
US7285278B2 (en) 2004-06-30 2007-10-23 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
US7335360B2 (en) 2004-06-30 2008-02-26 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
US7291338B2 (en) 2005-03-09 2007-11-06 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
US8809004B2 (en) 2010-04-02 2014-08-19 Idexx Laboratories, Inc. Detection of feline immunodeficiency virus

Similar Documents

Publication Publication Date Title
US12339282B2 (en) Coronavirus antibody detection kit based on magnetic particle chemiluminescence
CA2661875C (fr) Procede combinatoire de detection d'anticorps anti-virus de l'hepatite c et d'antigenes du virus de l'hepatite c
EP0202890A2 (fr) ELISA-compétitif pour détecter les anticorps
NZ228302A (en) Peptides associated with htlv-1
EP0593290B1 (fr) Proteine antigènique du noyau du virus de l'hépatite C, et méthode diagnostiquée et nécessaire
WO1993001304A1 (fr) Peptides synthetiques relatifs a des proteines d'enveloppe du vif
US6379886B1 (en) Diagnostic regeant for hepatitis C virus infection
Masihi et al. Enzyme-linked immunosorbent assay for the detection of influenza type-specific antibodies
EP0514509B1 (fr) Composition comprenant des antigenes conjugues a une activite enzymatique, et destinee aux necessaires a usage prive et epidemiologique de diagnostic immunologique, notamment de la maladie de chagas, et procede de preparation de ladite composition
JP3374101B2 (ja) Ｅｎｖ／ｇａｇポリペプチドマーカーを使用するネコ免疫不全ウイルス感染の診断
US5736348A (en) Method for the immunological diagnosis of Chagas' Disease using recombinant antigens
US4814269A (en) Diagnostic testing for antibodies against microorganisms
EP1590671A1 (fr) Procede ameliore de detection d'anticorps vhc dans un dosage combine ou dans un seul dosage d'anticorps
JP2003202345A (ja) Ｈｃｖコア抗原及び抗体の同時検出試薬
EP0313986B1 (fr) Dosages immunologiques utilisant des antigènes produits dans des organismes hétérologues
Obwaller et al. An enzyme-linked immunosorbent assay with whole trophozoites of Toxoplasma gondii from serum-free tissue culture for detection of specific antibodies
EP0443880B1 (fr) Méthode d'analyse du virus de l'anémie infectieuse équine (EIA-Virus)
WO1998058259A1 (fr) Stabilisation de polypeptides a utiliser dans des procedes de dosage immunologique
US6596846B2 (en) Method and composition for the diagnosis of equine infectious anemia virus disease by using the recombinant capsid protein virus (p26)
KR910007962A (ko) Hiv 관련 펩티드
CA1276103C (fr) Composant complementaire clq conjugue a une substance
Rho et al. Characterization of reverse transcriptase from feline leukemia virus by radioimmunoassay
LAURITZEN et al. Dot immunobinding (DIB), enzyme-linked immunosorbent assay (ELISA), and radioimmunoassay (RIA) for detecting peptide antigens and specific antibodies
Hilbink et al. A comparison of two enzyme linked immunosorbent assays for enzootic bovine leucosis serology
CA2082806A1 (fr) Dosages immunologiques des anticorps anti-vih-1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

122 Ep: pct application non-entry in european phase